ABSTRACT Schwannomas commonly develop in the cervical region, 25% – 45% of cases are diagnosed in this anatomical region. Tracheal neurogenic tumors are exceedingly rare and can be misdiagnosed as invasive thyroid carcinomas or other infiltrating malignancies when present at the level of the thyroid gland. Here, we present a case of synchronous benign cervical schwannoma with tracheal invasion and papillary thyroid carcinoma in a patient who was initially hospitalized for COVID-19. The patient presented with dyspnea that was later found to be caused by tracheal extension of a cervical tumor. Surgical excision was performed, and the surgical team proceeded with segmental tracheal resection, removal of the cervical mass, and total thyroidectomy. The specimen was sent for pathological analysis, which revealed synchronous findings of a benign cervical schwannoma with tracheal invasion and papillary thyroid carcinoma. The literature on this subject, together with the present case report, suggests that neurogenic tumors should be included in the differential diagnosis of obstructing tracheal cervical masses. Surgical excision is the first-line of treatment for benign cervical schwannomas. region 25 45 gland Here COVID19. COVID19 COVID 19. 19 COVID-19 tumor performed resection mass thyroidectomy analysis subject report masses firstline first line schwannomas 2 4 COVID1 1 COVID-1 COVID-

Abstract Objective: To investigate the prognostic factors to developing parotid and neck metastasis in locally advanced and relapsed Cutaneous Squamous Cell Carcinoma (CSCC) of the head and neck region. Methods: Single-center retrospective cohort study enrolling consecutive patients with advanced CSCC from 2009 to 2019. Seventy-four cases were identified. Study variables demographic data, clinical skin tumor stage, neck stage, parotid stage (P stage), surgical treatment features, and parotid, regional, and distant metastases. Survival measures: Overall Survival (OS) and Disease-Specific Survival (DSS). Results: The study group included 72.9% men (median age, 67 years); 67.5% showed T2/T3 tumors, 90.5% comorbidities, 20.2% immunosuppressed, with median follow-up: 35.8 months. The most frequent skin primary were auricular and eyelid regions, 75% underwent primary resection with flap reconstruction. Parotid metastasis was present in 50%, 32.4% showing parotid extracapsular spread, multivariate analysis found OR = 37.6 of positive parotid metastasis evolving into positive neck metastasis, p = 0.001. Occult neck metastasis, neck metastasis, and neck extracapsular spread were observed in 13.5%, 51.3%, and 37.8%, respectively. Kaplan-Meier survival: Clinical T4 versus T1, p = 0.028, P1 stage: 30% and 5% survival at 5 and 10 years, P3 stage: 0%, p = 0.016; OS and DSS showed negative survival for the parotid metastasis group, p = 0.0283. Conclusion: Our outcomes support a surgically aggressive approach for locally advanced and relapsed CSCC, with partial parotidectomy for P0, total parotidectomy for P1–3, selective I–III neck dissection for all patients and adjuvant radiochemotherapy to appropriately treat these patients with advanced CSCC of the head and neck region. Level of evidence: II b – Retrospective Cohort Study – Oxford Centre for Evidence-Based Medicine (OCEBM). Objective (CSCC region Methods Singlecenter Single center 200 2019 Seventyfour Seventy four identified data P , stage) features regional metastases measures (OS DiseaseSpecific Disease Specific DSS. . (DSS) Results 729 72 9 72.9 age 6 years years) 675 67.5 T2T3 TT T2 T3 T T2/T tumors 905 90 90.5 comorbidities 202 20 2 20.2 immunosuppressed followup follow up follow-up 358 35 8 35. months regions 75 reconstruction 50 50% 324 32 4 32.4 376 37 37. 0001 0 001 0.001 135 13 13.5% 513 51 3 51.3% 378 37.8% respectively KaplanMeier Kaplan Meier T1 0028 028 0.028 30 1 0% 0.016 0016 016 00283 0283 0.0283 Conclusion P0 P13 P1–3 IIII I III evidence EvidenceBased Evidence Based OCEBM. OCEBM (OCEBM) 201 (DSS 7 72. 67. T2T 90. 20. 32. 000 00 0.00 13.5 51.3 37.8 002 02 0.02 0.01 01 P1– (OCEBM 0.0 13. 51. 0.